GILD Gilead Sciences Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * WOLD OLSEN PER	2. Issuer Name and Ticker or Trading Symbol GILEAD SCIENCES INC [ GILD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE	3. Date of Earliest Transaction (MM/DD/YYYY) 2/6/2020
(Street) FOSTER CITY, CA 94044 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	2/6/2020		M		21720	A	$19.63	119574	D
Common Stock	2/6/2020		S		21720	D	$68.1218 (1)	97854	D
Common Stock	2/7/2020		M		20282	A	$20.645	118136	D
Common Stock	2/7/2020		S		20282	D	$69.00	97854	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified Stock Option (Right to Buy)	$19.63	2/6/2020		M			21720	(2)	5/11/2020	Common Stock	21720	$0	0	D
Non-qualified Stock Option (Right to Buy)	$20.645	2/7/2020		M			20282	(3)	5/12/2021	Common Stock	20282	$0	0	D

Explanation of Responses:
(1)	Sale prices reported for the transactions reported here range from $68.1000 to $68.1750. Full information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
(2)	The options vested quarterly over the first year of service and were fully vested on May 11, 2011.
(3)	The options vested quarterly over the first year of service and were fully vested on May 12, 2012.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
WOLD OLSEN PER GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY, CA 94044	X

Signatures
/s/ Amy Kim by Power of Attorney for Per Wold-Olsen		2/10/2020
**Signature of Reporting Person		Date